VIDEO: Stelara safe, effective for the long-term treatment of moderate to severe UC
Click Here to Manage Email Alerts
VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis.
According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At 4 years, 55% of patients in the long-term extension period achieved symptomatic remission, with 96% no longer receiving corticosteroids. Researchers also noted no new safety signals.
“In general, we can say that patients that were able to achieve remission at 1 year continued to stay in remission over the course of 4 years,” Afif, study author and associate professor of experimental medicine and gastroenterology at McGill University Health Center in Montreal, said. “No new safety signals were identified, and these patients did quite well over the long-term extension study.”
Collapse
Afif W, et al. Poster: PO369, PO395. Presented at: United European Gastroenterology Week; Oct. 8-11, 2022; Vienna (hybrid meeting).
Read more about
Click Here to Manage Email Alerts